STOCK TITAN

Standex (SXI) director logs small 50-share planned stock sale at $268.43

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Standex International director Thomas E. Chorman reported a small open-market sale of company stock. On this Form 4, he sold 50 shares of Standex International common stock at an average price of $268.43 per share on May 1, 2026, and held 12,516 shares afterward. The filing notes that this sale was made under an existing Rule 10b5-1 trading plan dated November 6, 2025, indicating the transaction was pre-planned rather than timed discretionarily.

Positive

  • None.

Negative

  • None.
Insider CHORMAN THOMAS E
Role null
Sold 50 shs ($13K)
Type Security Shares Price Value
Sale Common Stock 50 $268.43 $13K
Holdings After Transaction: Common Stock — 12,516 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Shares sold 50 shares Open-market sale on May 1, 2026
Sale price $268.43 per share Average sale price for the 50 shares
Shares held after sale 12,516 shares Direct holdings following the transaction
Rule 10b5-1 trading plan regulatory
"Sale of stock pursuant to existing 10b5-1 trading plan dated November 6, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Common Stock financial
"security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CHORMAN THOMAS E

(Last)(First)(Middle)
STANDEX INTERNATIONAL CORPORATION
23 KEEWAYDIN DRIVE, SUITE 300

(Street)
SALEM NEW HAMPSHIRE 03079

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
STANDEX INTERNATIONAL CORP/DE/ [ SXI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/01/2026S(1)50D$268.4312,516D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Sale of stock pursuant to existing 10b5-1 trading plan dated November 6, 2025.
/s/ Alan J. Glass05/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did SXI director Thomas E. Chorman report?

Thomas E. Chorman reported an open-market sale of 50 shares of Standex International (SXI) common stock. The shares were sold at an average price of $268.43 each, and the transaction was disclosed on a Form 4 insider trading report filed with regulators.

At what price did Thomas E. Chorman sell his SXI shares?

He sold 50 shares of SXI common stock at an average price of $268.43 per share. This price reflects the execution value reported in the Form 4 and gives investors a precise figure for the transaction’s per-share sale price.

How many Standex International (SXI) shares does Thomas E. Chorman hold after this sale?

After selling 50 shares, Thomas E. Chorman directly holds 12,516 shares of Standex International common stock. This post-transaction balance, disclosed in the Form 4, shows that the reported sale represents only a small portion of his overall direct holdings.

Was the SXI insider sale made under a Rule 10b5-1 trading plan?

Yes. The Form 4 footnote states the 50-share sale was executed under an existing Rule 10b5-1 trading plan dated November 6, 2025. Such pre-arranged plans are established in advance and are typically used to automate insider share sales over time.

What type of security did Thomas E. Chorman trade in this SXI Form 4?

The transaction involved Standex International common stock, classified as a non-derivative security. No options or other derivatives were reported, and the filing does not show any remaining derivative positions for Chorman after this specific sale.